A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/195 (2006.01) A61K 9/20 (2006.01) A61K 9/22 (2006.01) A61K 9/28 (2006.01) A61K 9/52 (2006.01)
Patent
CA 2086343
Disclosed are sustained release dosage forms of liothyronine, in combination with normal or sustained release of thyroxine in a molar ratio of about 1 to 50 : 1, especially 5 to 20 : 1, useful in thyroid hormone replacement therapy. Surprisingly, it is found that by incorporating liothyronine and optionally thyroxine into a prolonged action dosage form in the described ratios, that the side effects associated with thyroid hormone replacement therapy are greatly reduced or eliminated. The preparation can be a dosage form containing salts of both thyroxine and liothyronine which release in a sustained manner. The preparations will typically contain to 25 µg of liothryronine. Also disclosed are processes of manufacturing the pharmaceutical preparations. The compositions are useful in treating disease states such as hypothyroidism, hyperthyroidism (in combination with thyrostatic drugs), so-called "TSH" suppressive therapy, and depression.
Hennemann Georg
Krenning Eric Paul
Akzo N.v.
Fetherstonhaugh & Co.
LandOfFree
Sustained release thyroactive composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sustained release thyroactive composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release thyroactive composition will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1349316